3D MEDICINES(01244.HK)遭SELLAS(SLS.US)追討藥物臨床試驗里程碑式款項
3D MEDICINES(01244.HK)公布,有關公司於2020年12月與SELLAS Life Sciences Group(SLS.US)就3D189(galinpimout-S,「GPS」)和3D059(七價galinpisout-S,「GPS+」)在中國、香港、澳門和台灣的開發及商業化簽署一項獨家許可協議,公司已收到SELLAS及其子公司SLSG(權益主張方)於今年12月20日向香港國際仲裁中心提交的針對公司作為被申請人的仲裁通知,聲稱協議產生某些爭議,包括但不限於未能為3D189 III期臨床試驗的預期啟動支付里程碑式的款項。
公司認為,權益主張方的申索及指控是毫無根據及不合理的,公司對權益主張方不承擔任何責任並正在就通知尋求法律諮詢。公司對上述情況表示遺憾,並保留所有權利,包括在是次仲裁中對SELLAS提出反訴或尋求任何其他補救的權利。
此外,公司目前無法評估仲裁對集團的潛在影響。公司致力於根據其研發進展開發所有候選藥物,同時確保符合合同及監管要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.